

PRESS



EPIDAUROS Biotechnologie AG has appointed Dr. Michael Lutz as new Chief Executive Officer

April 27, 2006

Bernried, Germany - April 27, 2006 - EPIDAUROS Biotechnologie AG, a pharmacogenetics company located in Bernried near Munich, has appointed Dr. Michael Lutz (37) as new Chief Executive Officer. He replaces Dr. Manfred Zoltobrocki who has held this position since July 2003. Dr. Lutz has extensive knowledge of the pharma and biotech industry through various senior management positions at industry leading companies such as Novartis Pharma AG and Evotec AG. During this time he has gained broad experience in drug discovery and development with a particular focus on commercial and strategic aspects. Dr. Lutz joins EPIDAUROS from SuNyx GmbH, where he most recently worked as CEO and successfully sold its Bioanalytics business to Qiagen. Dr. Lutz received his Ph.D. in bio-organic chemistry from the ETH Zürich, Switzerland.

Falk Nuber, Head of Supervisory Board commented: "We are extremely delighted that Michael Lutz has joined EPIDAUROS. Based on his skill set and experience he is an ideal partner to advance the company to the next stage with a clear commercial and strategic focus. We also want to take the opportunity to thank Manfred Zoltobrocki for his work over the last years."

Contact EPIDAUROS:

Dr. Michael Lutz
EPIDAUROS Biotechnologie AG
CEO
Phone: ++49 (0)8158-9985-0
Fax: ++49 (0)8158-9985-48
Email: info@epidauros.com

PRESS



About EPIDAUROS Biotechnologie AG (www.epidauros.com)

EPIDAUROS Biotechnologie AG is a leading provider for tailor-made pharmacogenetics solutions in the area of drug development. The company investigates the individual genetic profile that influences a person's response to a drug in order to make drug development and therapy safer and more efficient. EPIDAUROS investigates and characterizes variations (polymorphisms) of genes that encode for drug transporter proteins, drug metabolizing enzymes and drug targets, e.g. receptors.

EPIDAUROS offers pharmaceutical and biotechnology companies comprehensive solutions for pharmacogenetics in clinical studies. Business activities range from pharmacogenetic consultancy for study planning, conduct of logistics for sample collection and shipment, sample processing and genetic testing in its own laboratory, up to data analysis and submission-ready reporting. In addition, provision of services includes development of new assays for genetic testing and extensive analysis of pharmacogenetic data, e.g. with regard to haplotypes (linked genetic markers).

It is EPIDAUROS' objective to support its customers in all aspects of pharmacogenetics and thereby contribute to fact-based decision making in clinical studies during drug development and in drug therapy. Application of pharmacogenetic profiling assays developed by EPIDAUROS during clinical development phases can help to specifically analyze a patient's risk for not responding to a new medication or to experience any adverse events. Thereby, prescription of drugs without any effect or with a negative impact on the patient can be avoided.

In close collaboration with academic institutes EPIDAUROS explores new polymorphisms with pharmacogenetic relevance and together with diagnostics companies EPIDAUROS develops genetic tests for routine use.

For further information, please contact:

EPIDAUROS Biotechnologie AG
Am Neuland 1, D-82347 Bernried
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com
www.epidauros.com